Federation of State Boards on Physical Therapy Certifies ReWalk’s Clinician Basic Training Program for CE credit in 22 states across the U.S.
YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MASSACHUSETTS, July 20, 2015 —In a first-of-its-kind decision, the Federation of State Boards of Physical Therapy has approved the clinician basic training program of ReWalk Robotics Ltd. (Nasdaq: RWLK) to qualify for Continuing Education Units (CEUs) for all physical therapists who complete the program. This decision, rendered by the national authority for physical training in the United States, makes ReWalk the only exoskeleton manufacturer with a training program approved to offer CEUs to physical therapists.
When physical therapists complete the ReWalk Basic Training Course they will qualify for CEUs as part of their required professional training and certification. ReWalk, the world leader in robotic exoskeletons for those impacted by spinal cord injury, has their Rehabilitation System placed in rehabilitation centers across the country. The company underwent an extensive application process to receive the approval from the Federation of State Boards of Physical Therapy, or FSBPT. The ReWalk Basic Training program is now eligible for CEUs across 22 states.
“We are proud that our training program is considered to be at a caliber to qualify for FSBPT certification – a first for our industry,” said ReWalk CEO Larry Jasinski. “It is an important moment for the company, knowing that our extensive training standards & program protocols met FSBPT’s strict requirements. This is a testament to the high standards the company sets for itself, and the tireless efforts of our talented, dedicated PT team toward providing best-in-class training.”
Physical therapists participating in the ReWalk Basic Training Program are eligible for CEUs effective immediately. Those interested in learning more about the 22 states participating in the CEU credits for ReWalk should contact the company’s headquarters.
“I’m proud to be part of company that hosts such a renowned training program,” said Jay Courant, ReWalk’s Worldwide Training Director. “It is a very exciting time in exoskeleton innovation, and now ReWalk Robotics has achieved yet another first with the FSBPT stamp of approval.”
ReWalk is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with Spinal Cord Injury (SCI) to stand upright and walk. The system provides user-initiated mobility through the integration of a wearable brace support, a computer-based control system and motion sensors. The system allows independent, controlled walking while mimicking the natural gait patterns of the legs. ReWalk is the only exoskeleton system cleared by the FDA for both personal use and use in a rehabilitation setting in the United States.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. ReWalk’s mission is to fundamentally change the health and life experiences of individuals with spinal cord injury. Founded in 2001, ReWalk has headquarters in the US, Israel and Germany. For more information on the ReWalk systems, please visit http://www.rewalk.com.
ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk’s future performance and, in some cases, may be identified by words like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek” and similar terms or phrases. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk’s control. Important factors that could cause ReWalk’s actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk’s expectations regarding future growth, including its ability to increase sales in its existing geographic markets and to expand to new markets; ReWalk’s ability to maintain and grow its reputation and the market acceptance of our products; ReWalk’s ability to achieve reimbursement from third-party payors for our products; ReWalk’s expectations as to its clinical research program and clinical results; ReWalk’s ability to improve its products and develop new products; ReWalk’s ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk’s ability to gain and maintain regulatory approvals; ReWalk’s ability to maintain relationships with existing customers and develop relationships with new customers; and other factors discussed under the heading “Risk Factors” in the U.S. Annual Report on the Form 20-F for the year ended December 31, 2014 filed with the U.S. Securities and Exchange Commission on February 27, 2015 and other documents filed with or furnished to the U.S. Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
